Skip to main content

Table 4 Four groups of logistic regression models based on tumor subtype and hemoglobin parameters, AUC of training data, and AUC of testing data

From: Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters

Tumor subtypes

Training AUC (95% CI)

Testing AUC (95% CI)

Group 1 (HER2 subtype)

 Her2

0.71 (0.66–0.75)

0.78 (0.74–0.81)

 Her2, tHb

0.88 (0.85–0.91)

0.88 (0.85–0.91)

 Her2, tHb, ER

0.91 (0.89–0/94)

0.87 (0.84–0.90)

 Her2, tHb, NS

0.91 (0.88–0.94)

0.85 (0.82–0.88)

 Her2, tHb, %tHb_cyc1

0.89 (0.87–0.92)

0.96 (0.95–0.98)

 Her2, tHb, %tHb_cyc2

0.89 (0.86–0.91)

0.94 (0.92–0.96)

 Her2, tHb, %tHb_cyc3

0.96 (0.94–0/97)

0.89 (0.86–0.92)

 Her2, tHb, %tHb_cyc1, %tHb_cyc2

0.90 (0.87–0.93)

0.97 (0.96–0.99)

 Her2, tHb, %tHb_cyc1, %tHb_cyc3

0.96 (0.94–0.97)

0.88 (0.85–0.91)

 Her2, tHb, %tHb_cyc2, %tHb_cyc3

0.96 (0.94–0.98)

0.88 (0.85–0.91)

 Her2, tHb, %tHb_cyc1, %tHb_cyc2, %tHb_cyc3

0.96 (0.94–0.98)

0.88 (0.86–0.92)

Group 2 (ER subtype)

 ER

0.67 (0.63–0.72)

0.55 (0.50–0.59)

 ER, tHb

0.81 (0.77–0.85)

0.69 (0.64–0.73)

 ER, tHb, NS

0.83 (0.80–0.87)

0.69 (0.65–0.73)

 ER, tHb, %tHb_cyc1

0.85 (0.82–0.89)

0.91 (0.88–0.93)

 ER, tHb, %tHb_cyc2

0.86 (0.83–0.89)

0.79 (0.75–0.83)

 ER, tHb, %tHb_cyc3

0.97 (0.95–0.98)

0.77 (0.73–0.81)

 ER, tHb, %tHb_cyc1, %tHb_cyc2

0.88 (0.85–0.91)

0.86 (0.83–0.89)

 ER, tHb, %tHb_cyc1, %tHb_cyc3

0.96 (0.95–0.98)

0.76 (0.73–0.80)

 ER, tHb, %tHb_cyc2, %tHb_cyc3

0.97 (0.95–0.98)

0.77 (0.73–0.81)

Group 3 (TN subtype)

 TN

0.55 (0.51–0.56)

0.46 (0.41–0.50)

 TN, tHb

0.77 (0.74–0.81)

0.72 (0.68–0.76)

 TN, tHb, NS

0.81 (0.78–0.85)

0.69 (0.65–0.75)

 TN, tHb, %tHb_cyc1

0.84 (0.81–0.87)

0.90 (0.87–0.93)

 TN, tHb, %tHb_cyc2

0.85 (0.82–0.88)

0.84 (0.81–0.88)

 TN, tHb, %tHb_cyc3

0.96 (0.94–0.98)

0.76 (0.72–0.80)

 TN, tHb, %tHb_cyc1, %tHb_cyc2

0.85 (0.82–0.88)

0.90 (0.87–0.93)

 TN, tHb, %tHb_cyc1, %tHb_cyc3

0.96 (0.94–0.98)

0.75 (0.71–0.79)

 TN, tHb, %tHb_cyc2, %tHb_cyc3

0.96 (0.94–0.98)

0.75 (0.71–0.79)

Group 4 (tHb and %tHb, all patients)

 tHb

0.77 (0.73–0.81)

0.75 (0.71–0.79)

 tHb, %tHb_cyc1

0.83 (0.80–0.87)

0.95 (0.93–0.97)

 tHb, %tHb_cyc2

0.84 (0.80–0.86)

0.87 (0.84–0.90)

 tHb, %tHb_cyc3

0.94 (0.92–0.97)

0.80 (0.76–0.84)

 tHb, %tHb_cyc1, %tHb_cyc2

0.84 (0.81–0.88)

0.92 (0.90–0.95)

 tHb, %tHb_cyc1, %tHb_cyc2, %tHb_cyc3

0.94 (0.92–0.96)

0.80 (0.76–0.84)

%tHb_cyc1

0.79 (0.75–0.83)

0.89 (0.86–0.92)

%tHb_cyc2

0.83 (0.80–0.86)

0.81 (0.78–0.85)

%tHb_cyc3

0.94 (0.92–0.96)

0.82 (0.78–0.85)

%tHb_cyc1, %tHb_cyc2

0.82 (0.78–0.87)

0.87 (0.83–0.90)

%tHb_cyc1, %tHb_cyc2, %tHb_cyc3

0.94 (0.92–0.96)

0.82 (0.79–0.86)

  1. Bold entries indicate the best set of predictors in each group
  2. AUC area under the curve, CI confidence interval, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, NS Nottingham score, tHb total hemoglobin, TN triple negative